Schering-Plough And Merck Plan Zetia/Lipitor Combination Following Patent Expiry
This article was originally published in The Pink Sheet Daily
Executive Summary
Ezetimibe/atorvastatin combination is intended as a complement to Vytorin, Schering-Plough says.
You may also be interested in...
Schering-Plough CEO Fred Hassan: An Interview With “The Pink Sheet” DAILY (Part 1 of 3)
Hassan discusses how the $14.4 billion Organon acquisition benefits the company as well as other potential M&A areas of interest for Schering-Plough.
Schering-Plough CEO Fred Hassan: An Interview With “The Pink Sheet” DAILY (Part 1 of 3)
Hassan discusses how the $14.4 billion Organon acquisition benefits the company as well as other potential M&A areas of interest for Schering-Plough.
Schering-Plough’s Cholesterol Franchise Holds 16.4 Percent Of New Scripts
Sales of Vytorin and Zetia climb 48 percent to $1.2 billion during the first quarter.